Teva Pharmaceutical Industries Limited financials
$39.81+2.39%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.14B | $3.98B | $4.71B | $4.48B | $4.18B | $3.89B | $4.23B | $4.33B | $4.16B | $3.82B | $4.46B | $3.85B |
| Gross profit | $2.15B | $1.97B | $2.65B | $2.30B | $2.10B | $1.88B | $2.12B | $2.15B | $2.02B | $1.77B | $2.42B | $1.85B |
| Gross margin | 52.0% | 49.5% | 56.4% | 51.4% | 50.3% | 48.2% | 50.1% | 49.6% | 48.6% | 46.4% | 54.2% | 48.1% |
| Operating income | -$231.0M | $652.0M | $299.0M | $882.0M | $455.0M | $521.0M | -$29.0M | -$49.0M | -$8.0M | -$218.0M | $756.0M | $344.0M |
| Net income | -$576.0M | $370.0M | $480.0M | $433.0M | $282.0M | $216.0M | -$217.0M | -$437.0M | -$846.0M | -$139.0M | $463.0M | $69.0M |
| Net margin | −13.9% | 9.3% | 10.2% | 9.7% | 6.8% | 5.6% | −5.1% | −10.1% | −20.3% | −3.6% | 10.4% | 1.8% |
| Diluted EPS | $-0.49 | $0.31 | $0.41 | $0.37 | $0.24 | $0.18 | $-0.19 | $-0.39 | $-0.75 | $-0.12 | $0.42 | $0.06 |
| EBITDA | $409.0M | $997.0M | $1.52B | $1.32B | $1.15B | $950.0M | $1.18B | $1.26B | $1.07B | $913.0M | $250.0M | $1.04B |
| Operating cash flow | $411.0M | -$40.0M | $1.16B | $369.0M | $227.0M | -$105.0M | $575.0M | $693.0M | $104.0M | -$124.0M | $1.18B | $5.0M |
| Free cash flow | $307.0M | -$208.0M | $1.02B | $233.0M | $131.0M | -$232.0M | $446.0M | $545.0M | $7.0M | -$248.0M | $1.06B | -$144.0M |
| Diluted shares | 1,165.0M | 1,179.0M | 1,168.0M | 1,164.0M | 1,161.0M | 1,159.0M | 1,135.0M | 1,133.0M | 1,133.0M | 1,123.0M | 1,106.0M | 1,135.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.65B | $3.74B | $3.56B | $2.20B | $2.16B | $1.70B |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $16.59B | $16.63B | $16.81B | $16.79B | $17.23B | $16.65B |
| Total assets | $39.86B | $40.04B | $40.75B | $39.86B | $40.13B | $38.41B |
| Total liabilities | $32.10B | $31.81B | $32.83B | $32.60B | $33.30B | $32.15B |
| Shareholders' equity | $7.76B | $8.23B | $7.91B | $7.25B | $6.83B | $6.27B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology